GemVax Appoints Dr. Lee Jaehong, "Leading Authority on Degenerative Brain Diseases," as CMO to Advance Clinical Development

GemVax & KAEL (hereinafter, GemVax) announced on November 3 that it had appointed Lee Jaehong, a clinical expert in degenerative brain diseases, as its chief medical officer (CMO). The company said the appointment is part of its efforts to strengthen its capabilities in developing treatments for neurodegenerative diseases, including progressive supranuclear palsy (PSP) and amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).

As the new CMO, Lee will oversee clinical development and operations in GemVax's biopharmaceutical business division and lead the development of its medical and scientific strategies. He will also play a key role in domestic and international clinical trials for the company's core pipeline, as well as in developing strategies to expand indications in the future.

Lee graduated from Seoul National University College of Medicine and earned a doctorate in medicine from Korea University. He subsequently served as a professor in the Department of Neurology at Asan Medical Center for more than 30 years, continuing his clinical work and research in degenerative brain diseases. He built clinical expertise in dementia and neurodegenerative diseases, including serving as director of the Parkinson's and Alzheimer's Center at Asan Medical Center.

His expertise has also been recognized through his academic and external activities. He has published a total of 253 papers, including in international academic journals, and has contributed to research on dementia and cognitive impairment and to the development of health policies, serving as chair of the Korean Dementia Association and as a member of the National Dementia Research and Development Committee, among other roles.

With Lee's appointment, GemVax plans to enhance the expertise and execution of its upcoming domestic and international clinical trials and develop concrete strategies to expand indications for treatments for neurodegenerative diseases.

A GemVax representative said, "We are very pleased to have appointed Dr. Lee Jaehong, a leading authority who has spent decades shaping clinical practice and academia in the field of neurodegenerative diseases. His clinical experience and academic insight will be a key driving force in structuring global clinical development and broadening our range of indications."

Lee said, "GemVax is a company that has consistently built a noteworthy track record in research into intractable neurodegenerative diseases, including progressive supranuclear palsy, Alzheimer's disease, and amyotrophic lateral sclerosis. Drawing on my clinical experience and expertise, I will do my utmost to further improve the quality and speed of clinical development and provide patients with practical treatment options."

This content was produced with the assistance of AI translation services.